Skip to main content


Media Contacts:

Asia Pacific

Joanne Cleary
Mobile: +61 428 816 751

Seqirus news releases

Seqirus news releases

CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia
07 Sep 2020

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful.

Additional flu vaccine supplies rolling out across Australia
27 May 2020

Seqirus Australia is pleased to confirm that additional supplies of flu vaccinations have started to roll out across the country – with around one million doses expected to be rolled out in the next three weeks, ahead of the peak influenza months.

Seqirus to supply additional flu vaccines
19 Apr 2020

Local flu vaccine manufacturer Seqirus will go back into production to supply Australians approximately two million additional flu vaccines for the 2020 flu season.

COVID-19 Update
02 Apr 2020

Safeguarding our people and communities remains our top priority.

24 Mar 2020

In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 986P01.

14 Feb 2020

In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 985P01.

Seqirus and Richter sign a license agreement for the commercialisation of a novel treatment for schizophrenia in Australia and New Zealand
24 May 2019

Seqirus Pty Ltd (Seqirus) and Gedeon Richter Plc (Richter) today announced the signing of an exclusive license agreement to commercialise a novel antipsychotic in Australia and New Zealand.

New PNG Snakebite Project to Improve Access to Antivenoms
17 Apr 2018

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.

Australians unprepared for potential dangers of venomous creatures this summer
27 Nov 2017

Seqirus launches #NoStingsSummer campaign encouraging Aussies to take care and watch out for bites and stings this summer

Seqirus launches first over-the-counter offering, Nervoderm®
03 Oct 2017

Seqirus has entered the over-the-counter market for the first time with a new Schedule 2, medicated patch, Nervoderm®.

Seqirus Manufacturing Director Recognised at 2017 Women in Industry Awards
23 Jun 2017

Lisa Lamb, Manufacturing Director for Products of National Significance at biopharmaceutical company Seqirus has been named winner of the Manufacturing Excellence category at the 2017 Women in Industry Awards hosted in Melbourne on Thursday 22 June.

Afluria Quad™ – a four strain flu vaccine manufactured in Australia is now available
26 Apr 2017

A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older.

CSL completes Novartis influenza vaccine business acquisition
03 Aug 2015

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.

Update on Novartis influenza vaccines acquisition
31 Jul 2015

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus.

CSL Acquires Exclusive Rights to Influenza Treatment
18 Jun 2015

CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).